Jim Wassil Sells 2,250 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $56.33, for a total transaction of $126,742.50. Following the completion of the sale, the chief operating officer directly owned 156,760 shares in the company, valued at $8,830,290.80. This represents a 1.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00.
• On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.83, for a total value of $127,867.50.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $60.67 on Wednesday. The business has a fifty day moving average price of $52.16 and a 200 day moving average price of $53.69. The company has a market cap of $8.76 billion, a P/E ratio of -8.82 and a beta of 1.22. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period last year, the firm earned ($1.04) EPS. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.

Institutional Trading of Vaxcyte

Several hedge funds have recently modified their holdings of PCVX. JPMorgan Chase & Co. lifted its stake in Vaxcyte by 30.6% in the third quarter. JPMorgan Chase & Co. now owns 1,565,036 shares of the company’s stock worth $56,373,000 after acquiring an additional 366,266 shares during the last quarter. Pivotal bioVenture Partners Investment Advisor LLC grew its holdings in Vaxcyte by 5.2% during the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,372,425 shares of the company’s stock worth $49,435,000 after acquiring an additional 67,300 shares in the last quarter. HighVista Strategies LLC increased its position in shares of Vaxcyte by 159.4% in the 3rd quarter. HighVista Strategies LLC now owns 86,802 shares of the company’s stock valued at $3,127,000 after purchasing an additional 53,345 shares during the last quarter. Bridgefront Capital LLC increased its position in shares of Vaxcyte by 127.2% in the 3rd quarter. Bridgefront Capital LLC now owns 24,325 shares of the company’s stock valued at $876,000 after purchasing an additional 13,617 shares during the last quarter. Finally, NEXTBio Capital Management LP acquired a new stake in shares of Vaxcyte in the 4th quarter valued at $4,406,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on PCVX. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.